Table 6.
Ongoing clinical trials assessing the efficacy of ALK inhibitors in lung cancer.
| Inhibitor | NCT number | Phase | Population | Treatment | Estimated enrollment | Primary outcome | Status |
|---|---|---|---|---|---|---|---|
| Alectinib | NCT02075840 | III | Untreated NSCLC with ALK mutation | Alectinib 600mg BID | 303 | PFS | Active, not recruiting |
| NCT02838420 | III | Advanced/metastatic ALK-positive NSCLC | Alectinib 600mg BID | 187 | PFS | Active, not recruiting | |
| NCT03456076 | III | Advanced/metastatic ALK-positive NSCLC | Alectinib 600mg BID | 255 | DSF | Recruiting | |
| Brigatinib | NCT03535740 (ALTA-2) | II | Advanced/metastatic ALK-positive NSCLC | Brigatinib 90mg QD | 104 | ORR | Active, not recruiting |
| NCT03596866 (ALTA-3) | III | Advanced/metastatic ALK-positive NSCLC | Brigatinib 90mg QD | 246 | PFS | Recruiting | |
| Lorlatinib | NCT03052608 | III | Advanced/metastatic ALK-positive NSCLC | Lorlatinib 100 mg QD | 280 | PFS | Recruiting |
| NCT03909971 | II | Advanced/metastatic ALK-positive NSCLC | Lorlatinib 100 mg QD | 100 | OR | Recruiting |
NSCLC, non-small cell lung cancer; ALK, anaplastic lymphoma kinase; QD, once daily; BID, twice daily; ORR, objective response rate; OS, overall survival; PFS, progression free survival; DSF, disease-free survival.